Main finding: There was a decline in vision in CRVO patients, but vision in BRVO patients remained stable. CRVO patients may require more frequent follow-up than every 3 months.
Purpose: To assess long-term safety and efficacy of intraocular ranibizumab injections in patients with macular edema after retinal vein occlusion
Study type: Open label extension trial
Condition: Central/Branch retinal vein occlusion
Participants: BRAVO/CRUISE participants
n=304 (from BRAVO), 304 (from CRUISE)
Intervention:
Patients were seen at least every 3 months and given intravitreal ranibizumab 0.5mg if they met retreatment criteria.
Vision in BRVO patients remained stable, while CRVO had a decline in vision. This could be due to reduced follow up and fewer ranibizumb injections in the second year of treatment.
BRVO
CRVO
Mean no. of injections
2-2.4
2.9-3.8
Change in BCVA score (letter)
-2.3 to +0.9
-5.2 to -4.1
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive